| Benjamin S Scharfstein, MD | |
|
1 Medical Park Blvd, 250 West, Bristol, TN 37620-7430 | |
| (423) 844-6620 | |
| (423) 844-6627 |
| Full Name | Benjamin S Scharfstein |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 26 Years |
| Location | 1 Medical Park Blvd, Bristol, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497850515 | NPI | - | NPPES |
| 3882258 | Medicaid | TN | |
| 266804 | Other | TN | INDIV ANTHEM/GROUP#093410 |
| TN0107 | Other | TN | JOHN DEERE NOW UNITED HC |
| 022276800 | Other | TN | BLACK LUNG GROUP |
| 7314019 | Medicaid | VA | |
| 0636398 | Other | TN | UMWA GROUP |
| 4059514 | Other | TN | BCBS OF TENNESSEE |
| P00007322 | Other | TN | MCRAILROAD/GROUP#CA8128 |
| 7032445 | Other | TN | AETNA |
| F03906748 | Other | TN | CHAMPUS GROUP |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 34037 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wellmont Bristol Regional Medical Center | Bristol, TN | Hospital |
| Smyth County Community Hospital | Marion, VA | Hospital |
| Johnston Memorial Hospital | Abingdon, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bristol Surgical Associates Pc | 7416038377 | 8 |
News Archive
Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.
GlaxoSmithKline confirmed today that a joint advisory committee to the U.S. Food and Drug Administration (FDA) voted to allow Avandia to remain on the market. Committee members voted for recommendations ranging from making no changes to the current label, to revising the label with additional warnings and restrictions to withdrawal from the U.S. market.
NIH-funded scientists have shown that boosting the production of certain broadly neutralizing antibodies can protect humanized mice from both intravenous and vaginal infection with HIV. Humanized mice have immune systems genetically modified to resemble those of humans, making it possible for them to become HIV-infected.
Investigators of the COSMOS (Continuous Observation of SMOking Subjects) study show good compliance and patient survival outcomes using a 5-year low-dose computed tomography (LDCT) screening protocol in individuals at high-risk of developing lung cancer.
› Verified 4 days ago
| Entity Name | Bristol Surgical Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972211340 PECOS PAC ID: 7416038377 Enrollment ID: O20140721002075 |
News Archive
Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.
GlaxoSmithKline confirmed today that a joint advisory committee to the U.S. Food and Drug Administration (FDA) voted to allow Avandia to remain on the market. Committee members voted for recommendations ranging from making no changes to the current label, to revising the label with additional warnings and restrictions to withdrawal from the U.S. market.
NIH-funded scientists have shown that boosting the production of certain broadly neutralizing antibodies can protect humanized mice from both intravenous and vaginal infection with HIV. Humanized mice have immune systems genetically modified to resemble those of humans, making it possible for them to become HIV-infected.
Investigators of the COSMOS (Continuous Observation of SMOking Subjects) study show good compliance and patient survival outcomes using a 5-year low-dose computed tomography (LDCT) screening protocol in individuals at high-risk of developing lung cancer.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Benjamin S Scharfstein, MD 1 Medical Park Blvd, 250 West, Bristol, TN 37620-7430 Ph: (423) 844-6620 | Benjamin S Scharfstein, MD 1 Medical Park Blvd, 250 West, Bristol, TN 37620-7430 Ph: (423) 844-6620 |
News Archive
Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.
GlaxoSmithKline confirmed today that a joint advisory committee to the U.S. Food and Drug Administration (FDA) voted to allow Avandia to remain on the market. Committee members voted for recommendations ranging from making no changes to the current label, to revising the label with additional warnings and restrictions to withdrawal from the U.S. market.
NIH-funded scientists have shown that boosting the production of certain broadly neutralizing antibodies can protect humanized mice from both intravenous and vaginal infection with HIV. Humanized mice have immune systems genetically modified to resemble those of humans, making it possible for them to become HIV-infected.
Investigators of the COSMOS (Continuous Observation of SMOking Subjects) study show good compliance and patient survival outcomes using a 5-year low-dose computed tomography (LDCT) screening protocol in individuals at high-risk of developing lung cancer.
› Verified 4 days ago
Dr. Sidney W Collins Jr., MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Park Blvd, 250 West, Bristol, TN 37620 Phone: 423-844-6620 Fax: 423-844-6626 | |
Robert H Blanton, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Park Blvd, 250 West, Bristol, TN 37620 Phone: 423-844-6620 Fax: 423-844-6627 | |
Ms. Elizabeth Dray, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Park Blvd, Bristol, TN 37620 Phone: 423-844-1121 | |
Michael E Chupp, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 312 Mia Dr, Bristol, TN 37620 Phone: 423-366-6005 | |
Michael D Rowell, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Park Blvd, 250 West, Bristol, TN 37620 Phone: 423-844-6620 Fax: 423-844-6627 | |
David Nelson Gwaltney, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Park Blvd, 250 West, Bristol, TN 37620 Phone: 423-844-6620 Fax: 423-844-6627 |